| Name | Title | Contact Details |
|---|
Klas Government makes the worlds most powerful technology for the tactical edge. We provide rugged, low size, weight and power (SWaP) deployable communications solutions to meet the needs of government and military communicators in any operational environment. Klas Government enables customers to communicate more and carry less by delivering tactical and executive communications systems specifically designed for ultimate flexibility, scalability and portability. Klas Governments capabilities include product design and configuration, network management, solutions development, fielding and training. The company employs dedicated personnel who offer engineering and support 24/7/365. Klas Government is a U.S. subsidiary of Klas Ltd. and was founded in 2009 to manage and effectively address U.S. government and federal requirements at all classification levels. Klas Government employs staff across two offices located in Herndon, VA and Tampa, FL with corporate offices located in Washington, D.C. and internationally in Dublin, Ireland. www.klasgov.com.
Brightside Health delivers life-changing mental health care to people with mild to severe clinical depression, anxiety, and other mood disorders, including those with elevated suicide risk. Powered by proprietary AI, purpose-built technology, and a world-class clinician network, Brightside Health combines precision psychiatry and leading-edge therapeutic techniques to offer timely care and improve patient outcomes across the entire clinical spectrum, affordably and at scale. Brightside Health accepts insurance in all 50 states and DC, covering 60+ million lives with Cigna / Evernorth, Aetna, UnitedHealthcare / Optum, and more. Members can also pay for services out-of-pocket.
Quik Print of Austin, Inc. is a Austin, TX-based company in the Business Services sector.
technical editor is a Alexandria, VA-based company in the Business Services sector.
Ardelyx was founded in 2007 by Dominique Charmot, Ph.D., Peter Schultz, Ph.D. and Jean Frechet, Ph.D., to discover, develop and commercialize innovative, non-systemic, small molecule therapeutics that work exclusively in the gastrointestinal, GI tract to treat cardio-renal, GI and metabolic diseases.We have developed a proprietary drug discovery and design platform enabling us, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing our platform, we discovered and designed our lead product candidate, tenapanor, which in preclinical and clinical studies has consistently demonstrated the ability to reduce the absorption of dietary sodium and phosphorus, both of which are key factors in the progression of kidney disease.